CTLA4 and melanoma: This correlation between the immune evasion mechanism and the therapeutic effect of ipilimumab highlights how targeting CTLA-4 can help overcome immune suppression and enhance anti-tumor immunity.381 Investigations have shown that ipilimumab can provide long-term responses and increase survival in melanoma patients.